NeuroPace (NPCE) Set to Announce Quarterly Earnings on Wednesday

NeuroPace (NASDAQ:NPCE) will release its earnings data after the market closes on Wednesday, May 8th. Analysts expect NeuroPace to post earnings of ($0.32) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

NeuroPace (NASDAQ:NPCE) last issued its earnings results on Tuesday, March 5th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.10. NeuroPace had a negative return on equity of 153.76% and a negative net margin of 50.38%. The business had revenue of $18.01 million for the quarter, compared to analyst estimates of $17.74 million. On average, analysts expect NeuroPace to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NeuroPace Price Performance

Shares of NASDAQ NPCE opened at $13.64 on Monday. The company has a debt-to-equity ratio of 2.76, a quick ratio of 5.02 and a current ratio of 5.71. NeuroPace has a fifty-two week low of $3.80 and a fifty-two week high of $18.15. The firm has a market capitalization of $391.74 million, a PE ratio of -10.66 and a beta of 2.06. The stock’s 50-day simple moving average is $13.98 and its 200-day simple moving average is $11.92.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. SVB Leerink assumed coverage on NeuroPace in a research report on Tuesday, January 30th. They set an “outperform” rating and a $22.00 target price on the stock. Leerink Partnrs reissued an “outperform” rating on shares of NeuroPace in a research report on Tuesday, January 30th. Cantor Fitzgerald raised their target price on NeuroPace from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. Morgan Stanley raised their target price on NeuroPace from $9.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 6th. Finally, Wells Fargo & Company raised NeuroPace from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $16.00 to $20.00 in a research report on Thursday, March 14th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, NeuroPace has an average rating of “Moderate Buy” and a consensus target price of $15.67.

Insider Buying and Selling

In related news, major shareholder Orbimed Advisors Llc sold 4,674 shares of the firm’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $14.03, for a total transaction of $65,576.22. Following the transaction, the insider now owns 3,406,335 shares in the company, valued at approximately $47,790,880.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 525,345 shares of company stock worth $7,583,250 in the last quarter. 27.50% of the stock is owned by insiders.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.